TREATMENT OF RENAL CARCINOMA IN A BINTURONG (ARCTICTIS BINTURONG) WITH NEPHRECTOMY AND A TYROSINE KINASE INHIBITOR

被引:1
|
作者
Thompson, Kimberly A. [1 ]
Patterson, Jon [2 ]
Fitzgerald, Scott D. [2 ]
Needle, David [2 ,3 ]
Harrison, Tara [1 ,4 ]
机构
[1] Michigan State Univ, Coll Vet Med, 784 Wilson Rd, E Lansing, MI 48824 USA
[2] Michigan State Univ, Diagnost Ctr Populat & Anim Hlth, Coll Vet Med, 4125 Beaumont Rd, Lansing, MI 48824 USA
[3] Univ New Hampshire, New Hampshire Vet Diagnost Lab, 21 Bot Lane, Durham, NH 03824 USA
[4] North Carolina State Univ, Dept Clin Sci, 1060 William Moore Dr, Raleigh, NC 27607 USA
关键词
Arctictis binturong; binturong; nephrectomy; renal adenocarcinoma; toceranib phosphate; tyrosinekinase inhibitor; CELL CARCINOMA; HYPERCALCEMIA; CANINE;
D O I
10.1638/2015-0285.1
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
A 13-yr-old female binturong (Arctictis binturong) presented with a 1 wk history of decreased appetite. The animal was thin, with hypercalcemia (calcium 12.2 mg/dl). A right renal mass was identified on ultrasound and removed via nephrectomy. Histopathology indicated a renal adenocarcinoma. Treatment with toceranib phosphate, a tyrosine-kinase inhibitor, was initiated and well tolerated by the animal. Four months after initial diagnosis radiographs indicated metastases to the lungs and the animal was euthanized. Necropsy revealed disseminated adenocarcinoma. Although treatment did not prevent metastasis, it was minimally invasive and well tolerated by the animal with minimal side effects. Review of records at the institution revealed that the cause of death for the primary case's dam and sire was disseminated renal carcinoma. These cases suggest that there may be a hereditary component to development of renal neoplasia in binturongs. Renal carcinoma should be considered an aggressive neoplasia in binturongs with a poor prognosis.
引用
收藏
页码:1109 / 1113
页数:5
相关论文
共 50 条
  • [31] Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
    Fontes-Sousa, Mario
    Magalhaes, Helena
    Oliveira, Alicia
    Carneiro, Filipa
    dos Reis, Filipa Palma
    Madeira, Pedro Silvestre
    Meireles, Sara
    ADVANCES IN THERAPY, 2022, 39 (03) : 1107 - 1125
  • [32] Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy
    Laukhtina, Ekaterina
    Quhal, Fahad
    Mori, Keiichiro
    Motlagh, Reza Sari
    Rajwa, Pawel
    Yanagisawa, Takafumi
    Mostafaei, Hadi
    Konig, Frederik
    Aydh, Abdulmajeed
    Pradere, Benjamin
    Enikeev, Dmitry
    Karakiewicz, Pierre, I
    Schmidinger, Manuela
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (01): : 120 - 124
  • [33] Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma
    Reed, Jarred P.
    Posadas, Edwin M.
    Figlin, Robert A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (03) : 259 - 271
  • [34] Renal cell carcinoma with multiple bone metastases effectively treated by a combination of tyrosine kinase inhibitor, robot-assisted partial nephrectomy, and metastasectomy
    Sawada, Atsuro
    Takeda, Masashi
    Goto, Takayuki
    Akamatsu, Shusuke
    Kobayashi, Takashi
    CLINICAL CASE REPORTS, 2024, 12 (03):
  • [35] Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study
    Hatakeyama, Shingo
    Naito, Sei
    Numakura, Kazuyuki
    Kato, Renpei
    Koguchi, Tomoyuki
    Kojima, Takahiro
    Kawasaki, Yoshihide
    Kandori, Shuya
    Kawamura, Sadafumi
    Tsushima, Eiki
    Nishiyama, Hiroyuki
    Ito, Akihiro
    Kojima, Yoshiyuki
    Habuchi, Tomonori
    Obara, Wataru
    Tsuchiya, Norihiko
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (04) : 369 - 375
  • [36] Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
    Sekino, Yohei
    Teishima, Jun
    Liang, Gangning
    Hinata, Nobuyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (12) : 1419 - 1428
  • [37] Novel role of a tyrosine kinase inhibitor by reversion of immune suppression in renal cell carcinoma
    Seliger, B.
    Mueller, A.
    Giersberg, Corinna
    Handke, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Focused Ultrasound-Triggered Release of Tyrosine Kinase Inhibitor From Thermosensitive Liposomes for Treatment of Renal Cell Carcinoma
    Abshire, Caleb
    Murad, Hakm Y.
    Arora, Jaspreet S.
    Liu, James
    Mandava, Sree Harsha
    John, Vijay T.
    Khismatullin, Damir B.
    Lee, Benjamin R.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (05) : 1355 - 1362
  • [39] Tyrosine-kinase inhibitor sorafenib (S) in treatment of metastatic renal cell carcinoma cancer (mRCC) with lung metastases
    Popova, Irina L.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Tyrosine kinase inhibitor sunitinib targets the vasculature of clear cell renal cell carcinoma: a morphometrical study of treatment effect
    Chen, Lu
    Chen, Longwen
    Huang, Jie
    Xu, Danfeng
    Wang, Linhui
    Zhou, Ming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (03): : 3571 - 3578